A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib

Published:2020-02 Issue: Volume:126 Page:45-55
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Penel Nicolas,Mir Olivier,Wallet Jennifer,Ray-Coquard Isabelle,Le Cesne Axel,Italiano Antoine,Salas Sebastien,Delcambre Corinne,Bompas Emmanuelle,Bertucci François,Saada-Bouzid Esma,Chaigneau Loïc,Chevreau Christine,Brodowicz Thomas,Decoupigny Emilie,Vanseymortier Marie,Laroche Lucie,Taieb Sophie,Le Deley Marie-Cécile,Blay Jean-Yves

Funder

Bayer HealthCare

N.P.

PharmaMar

Pfizer

Lilly

Ariad

Roche

Novartis

Bayer

Amgen

BMS

French National Cancer Institute

INCa

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing;Ducimetière;PLoS One,2011

2. Presentation and outcome of frequent and rare sarcoma histologic subtypes: a study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers;Penel;Cancer,2018

3. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up;Casali;Ann Oncol,2018

4. Soft-tissue sarcomas in adults;Clark;N Engl J Med,2005

5. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial;van der Graaf WT1;Lancet,2012

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of tyrosine kinase inhibitors in patients with advanced or metastatic sarcomas after prior chemotherapy: A meta-analysis;Medicine;2024-03-15

2. New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis;Biomedicine & Pharmacotherapy;2023-07

3. Regorafenib for the Treatment of Sarcoma;Current Treatment Options in Oncology;2022-09-30

4. First and further-line multidisciplinary treatment of retroperitoneal sarcomas;Current Opinion in Oncology;2022-07

5. Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies;Current Oncology;2021-11-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3